X-linked hypophosphataemia

被引:4
|
作者
Kamenicky, Peter [1 ,2 ]
Briot, Karine [4 ]
Munns, Craig F. [5 ,6 ,7 ]
Linglart, Agnes [1 ,3 ]
机构
[1] Univ Paris Saclay, INSERM, Physiol & Physiopathol Endocriniennes, F-94276 Le Kremlin Bicetre, France
[2] Hop Bicetre, Assistance Publ Hop Paris, Ctr Reference Malad Metab Calcium & Phosphate, Serv Endocrinol & Malad Reprod, Le Kremlin Bicetre, France
[3] Hop Bicetre, Assistance Publ Hop Paris, Serv Endocrinol & Diabet Enfant, Le Kremlin Bicetre, France
[4] Hop Cochin, Assistance Publ Hop Paris, Ctr Reference Malad Metab Calcium & Phosphate, Serv Rhumatol, Paris, France
[5] Univ Queensland, Queensland Childrens Hosp, Dept Endocrinol & Diabet, Brisbane, Qld, Australia
[6] Univ Queensland, Child Hlth Res Ctr, Brisbane, Qld, Australia
[7] Univ Queensland, Fac Med, Brisbane, Qld, Australia
来源
LANCET | 2024年 / 404卷 / 10455期
关键词
GROWTH-HORMONE TREATMENT; ANTI-FGF23 ANTIBODY KRN23; D-RESISTANT RICKETS; VITAMIN-D; PARATHYROID-HORMONE; ASARM-PEPTIDES; SHORT CHILDREN; ADULT PATIENTS; HR-PQCT; PHOSPHATE;
D O I
10.1016/S0140-6736(24)01305-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
X-linked hypophosphataemia is a genetic disease caused by defects in the phosphate regulating endopeptidase homolog X-linked ( PHEX ) gene and is characterised by X-linked dominant inheritance. The main consequence of PHEX deficiency is increased production of the phosphaturic hormone fibroblast growth factor 23 (FGF23) in osteoblasts and osteocytes. Chronic exposure to circulating FGF23 is responsible for renal phosphate wasting and decreased synthesis of calcitriol, which decreases intestinal phosphate absorption. These mechanisms result in lifelong hypophosphataemia, impaired growth plate and bone matrix mineralisation, and diverse manifestations in affected children and adults, including some debilitating morbidities and possibly increased mortality. Important progress has been made in disease knowledge and management over the past decade; in particular, targeting FGF23 is a therapeutic approach that has substantially improved outcomes. However, patients affected by this complex disease need lifelong care and innovative treatment strategies, such as gene repair of PHEX, are necessary to further limit the disease burden.
引用
收藏
页码:887 / 901
页数:15
相关论文
共 50 条
  • [1] X-linked hypophosphataemia in South Africa
    Basu, D
    Pettifor, JM
    Kromberg, J
    SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2004, 94 (06): : 460 - 464
  • [2] Hope for patients with X-linked hypophosphataemia?
    Pettifor, John M.
    LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (03): : 163 - 165
  • [3] Pharmacological management of X-linked hypophosphataemia
    Imel, Erik A.
    White, Kenneth E.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (06) : 1188 - 1198
  • [4] THE CASE OF X-LINKED HYPOPHOSPHATAEMIA (XLH)
    Vasylets, V.
    Tikhonchuk, N.
    OSTEOPOROSIS INTERNATIONAL, 2021, 32 (SUPPL 1) : S185 - S186
  • [5] Burosumab Approved indication: X-linked hypophosphataemia
    不详
    AUSTRALIAN PRESCRIBER, 2022, 45 (01) : 25 - 26
  • [6] BUROSUMAB IN TWO PATIENTS WITH X-LINKED HYPOPHOSPHATAEMIA
    Acunas-Soto, Silvia
    Castellano-Martinez, Ana
    Roldan-Cano, Virginia
    Rodriguez-Gonzalez, Moises
    PEDIATRIC NEPHROLOGY, 2021, 36 (10) : 3469 - 3469
  • [7] X-LINKED HYPOPHOSPHATAEMIA WITH MULTIPLE SKELETAL MANIFESTATIONS
    Watts, Laura
    Wordsworth, Paul
    RHEUMATOLOGY, 2015, 54 : 57 - 58
  • [8] X-LINKED HYPOPHOSPHATAEMIA: CHALLENGES IN MANAGING A CHRONIC DISEASE
    Vilaca, Tatiane
    Eastell, Richard
    OSTEOPOROSIS INTERNATIONAL, 2018, 29 : 616 - 616
  • [9] Burosumab: a new stratedy in the treatment of X-Linked Hypophosphataemia
    Pensa, Marta
    Carbone, Vincenza
    Maggi, Isabella
    Camporeale, Anna
    Martino, Marida
    Torres, Diletta Domenica
    Santangelo, Luisa
    Giordano, Mario
    PEDIATRIC NEPHROLOGY, 2024, 39 (01) : S342 - S342
  • [10] X-linked hypophosphataemia: a homologous disorder in humans and mice
    Tenenhouse, HS
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (02) : 333 - 341